Virios Therapeutics company info

What does Virios Therapeutics do?
Virios Therapeutics (NASDAQ:VIRI) is focused on developing antiviral therapies to treat diseases caused by the herpes simplex virus and other viral conditions. Their primary project involves the use of IMC-1, a novel, proprietary, fixed-dose combination of famciclovir and celecoxib, aimed to suppress herpes virus replication and the associated symptomatic disease. The team at Virios Therapeutics is dedicated to advancing their lead candidate through clinical trials, with the ultimate goal of addressing the unmet medical needs of patients suffering from fibromyalgia and potentially other chronic illnesses linked to viral triggers. Their objective is to not only improve patient outcomes through effective treatment options but also to deepen the understanding of viral contributions to chronic diseases.
Virios Therapeutics  company media
Company Snapshot

Is Virios Therapeutics a public or private company?

key
Ownership
Public

How many people does Virios Therapeutics employ?

people
Employees
4

What sector is Virios Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Virios Therapeutics ?

location pin
Head Office
Georgia, United States

What year was Virios Therapeutics founded?

founded flag
Year Founded
2012
What does Virios Therapeutics specialise in?
/Fibromyalgia Treatment /Antiviral Drugs /Pharmaceutical Research /Healthcare Solutions /Medicinal Breakthroughs /Clinical Trials

What are the products and/or services of Virios Therapeutics ?

Overview of Virios Therapeutics offerings
Developing IMC-1, a novel antiviral combination therapy aimed at treating fibromyalgia by targeting underlying herpes virus co-infections.
Conducting clinical trials to evaluate the efficacy and safety of IMC-1 in fibromyalgia patients.
Researching the application of antiviral therapies in other chronic conditions potentially linked to viral infections to expand treatment portfolio.
Investigation of the mechanism of action of antiviral compounds in modifying disease pathways associated with chronic illnesses.
Exploring partnerships and collaborations with other pharmaceutical and research entities to enhance drug development and discovery projects.
Engaging in patient advocacy and support initiatives to raise awareness and understanding of fibromyalgia and related disorders.

Who is in the executive team of Virios Therapeutics ?

Virios Therapeutics leadership team
  • Mr. Gregory  Duncan
    Mr. Gregory Duncan
    Chairman & CEO
  • Dr. William L. Pridgen M.D.
    Dr. William L. Pridgen M.D.
    Founder & Director
  • Dr. R. Michael Gendreau M.D., Ph.D.
    Dr. R. Michael Gendreau M.D., Ph.D.
    Chief Medical Officer
  • Mr. Ralph D. Grosswald M.P.H.
    Mr. Ralph D. Grosswald M.P.H.
    Senior Vice President of Operations
  • Ms. Carol  Duffy Ph.D.
    Ms. Carol Duffy Ph.D.
    Chief Scientific Advisor